Table 2.
Summary table of studies on patients’ prognosis and treatment responses using IMC technology in human and mouse cancerous tissues.
| Prognosis and treatment responses | Ref | Authors | Year | Results |
|---|---|---|---|---|
| Response to ICI treatments | 16 | Hoch et al. (16) | 2021 | Chemokine landscape and immune infiltration characterization in metastatic melanoma sample |
| 40 | Martinez-Morilla et al. (40) | 2021 | ICI potential biomarkers identification in metastatic melanoma | |
| 41 | Sanmamed et al. (41) | 2021 | Treatment resistance in non–small cell lung cancer | |
| 42 | Noac’h et al. (42) | 2020 | Patients’ outcomes in small-cell lung cancer | |
| 43 | Bortolomeazzi et al (43) | 2020 | Responses to anti-PDL1 agents in colorectal cancer | |
| 44 | Umemoto et al. (44) | 2020 | Comparison of the TME in early- to late-stage biliary tract cancer | |
| 45 | Zhu et al. (45) | 2019 | Immune biomarkers in pre- and on-treatment ICI in recurrent platinum-resistant epithelial ovarian cancer | |
| 46 | Zhang et al. (46) | 2021 | TME changes induced by neoadjuvant therapy in hepatocellular carcinoma | |
| IMC combination | 9 | Giesen et al. (9) | 2014 | IHC and immunocytochemistry coupled with IMC in breast cancer |
| 14 | Ali et al. (14) | 2020 | Genomic assays coupled with IMC in breast cancer | |
| 15 | Schulz et al. (15) | 2018 | Simultaneous detection and quantification of proteins, protein phosphorylations and transcripts in breast cancer | |
| 19 | Schulz et al. (19) | 2021 | Multispectral immunofluorescence coupled with IMC and omics data | |
| 47 | Kuett et al. (47) | 2022 | 3D IMC in breast cancer | |
| Response to non-ICI treatments | 48 | Carvajal-Hausdorf et al. (48) | 2019 | Cytotoxic T-cells improve effect of Trastuzumab in HER2+ breast cancer |
| 49 | Hav et al. (49) | 2019 | TME characterization according to patients’ outcomes in diffuse large B cell lymphoma | |
| 50 | Colombo et al. (50) | 2021 | PD-L1/PD-1 levels in refractory and complete responders in diffuse large B cell lymphoma | |
| 51 | Hav et al. (51) | 2019 | CD8 spatial network alone could predict overall survival in diffuse large B cell lymphoma | |
| 22,52 | Zhu et al. (22, 52) | 2020-21 | Cellular comparison of LTS and STS in ovarian cancer | |
| 21 | Strobl et al. (21) | 2018 | Tumor-stroma interactions affect outcomes in ovarian cancer | |
| Platinum-based treatment | 53,54 | Cao et al. (53, 54) | 2019 | Platinum deposition after Oxaliplatin in gastrointestinal malignancies |
| Mouse models | 55 | Chang et al. (55) | 2016 | Distribution of cisplatin in pancreas cancer PDX mice model |
| 56 | Dey et al. (56) | 2020 | IL4, IL13 in KRAS-mutated pancreatic cancer mouse cell line | |
| 57 | Peran et al. (57) | 2021 | CDH11 level of CAFs in human and mouse pancreatic cancer | |
| 58 | Raj et al. (58) | 2019 | Improve effect of CAR-Tcells in metastatic pancreatic ductal adenocarcinoma PDX mice model | |
| 59 | Rinkenbaugh et al. (59) | 2020 | Pathway activation in triple negative breast cancer PDX mice model | |
| 60 | Liu et al. (60) | 2021 | Minimally invasive therapeutics delivery approach of CD40/PDL1to improve clinical response in a murine model of advanced triple negative breast cancer | |
| 61 | Guo et al. (61) | 2021 | MNK1/2-eIF4E axis involvement in postpartum breast cancer mouse model | |
| 62 | Somasundaram et al. (62) | 2021 | Resistance to anti-PD1 agents in mouse melanoma model |
TILs, Tumor-infiltrating lymphocytes; TME, Tumor microenvironment; LTS, long term survivors; STS, short term survivors; PDX, patient-derived xenograft.